Post hoc analysis of a randomized, double-blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes: endo-metabolic features at baseline identify a subgroup of responders

Post hoc analysis of a randomized, double-blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes: endo-metabolic features at baseline identify a subgroup of responders

AimIn a recent randomized, multicenter trial (NCT02814838) a short-term anti-inflammatory treatment with ladarixin (LDX; an inhibitor of the CXCR1/2 chemokine receptors) did not show benefit on preserving residual beta cell function in new-onset type 1 diabetes. We present a post hoc analysis of tri...

Full description

Bibliographic Details
Main Authors: Valeria Sordi, Paolo Monti, Vito Lampasona, Raffaella Melzi, Silvia Pellegrini, Bart Keymeulen, Pieter Gillard, Thomas Linn, Emanuele Bosi, Ludger Rose, Paolo Pozzilli, Francesco Giorgino, Efisio Cossu, Lorenzo Piemonti
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Endocrinology
Subjects:
IL-8
CXCR1
CXCR2
type 1 diabetes mellitus
trial
post hoc analyses
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2023.1175640/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2023.1175640/full

Similar Items